ICON PLC Files 6-K with Q3 2024 Financials

TL;DR

ICON PLC dropped Q3 2024 numbers, check the balance sheet.

AI Summary

ICON PLC filed a 6-K report on October 25, 2024, for the period ending September 30, 2024. The filing includes financial data for the third quarter of 2024 and year-to-date figures. Key financial items such as common stock, additional paid-in capital, and retained earnings are reported as of December 31, 2023, and for various periods in 2024.

Why It Matters

This filing provides investors with updated financial performance data for ICON PLC, crucial for assessing the company's current health and future prospects.

Risk Assessment

Risk Level: low — This is a routine financial filing (6-K) that provides standard financial reporting and does not indicate any unusual risks.

Key Numbers

• Q3 2024 — Quarterly Financials (Reporting period for updated financial data.)
• 2024-09-30 — Year-to-Date (Period covered by the financial data.)

Key Players & Entities

• ICON PLC (company) — Filer of the report
• 2024-09-30 (date) — End of reporting period
• 2024-10-25 (date) — Filing date
• 2023-12-31 (date) — Balance sheet date

FAQ

Key Financial Figures

• $500 million — thorized a new buyback program of up to $500 million of the outstanding ordinary shares of t
• $100.0 million — he Company for a total consideration of $100.0 million. On October 22, 2024, the Company's B
• $250.0 million — an additional buyback program of up to $250.0 million of the outstanding ordinary shares of t
• $650.0 million — permits the Company to repurchase up to $650.0 million worth of ordinary shares. A resolutio
• $2 billion — ly-owned subsidiary of ICON plc, issued $2 billion of Senior Secured Notes ("the New Notes
• $750 million — sued in aggregate principal amounts of: $750 million 5.809% Senior Secured Notes due 2027 (t
• $5,515 million — a senior secured term loan facility of $5,515 million and a senior secured revolving credit f
• $300 million — ility in an initial aggregate amount of $300 million (subsequently increased on May 2, 2023
• $7.4 million — made mandatory principal repayments of $7.4 million (nine months ended September 30, 2024:
• $2,297.3 million — : mandatory and voluntary repayments of $2,297.3 million) o f the senior secured term loan facil
• $16.9 million — ted with previously capitalized fees of $16.9 million. In addition, during the quarter ende
• $50.0 million — ed September 30, 2024, the Company drew $50.0 million (nine months ended September 30, 2024:
• $243.0 million — (nine months ended September 30, 2024: $243.0 million) of the senior secured revolving loan f
• $298.0 million — (nine months ended September 30, 2024: $298.0 million). At September 30, 2024, $nil was drawn

Filing Documents

• iclr-20240930.htm (6-K) — 1294KB
• icon-ex22guarantorschedule.htm (EX-22.1) — 93KB
• 0001060955-24-000090.txt ( ) — 7598KB
• iclr-20240930.xsd (EX-101.SCH) — 55KB
• iclr-20240930_cal.xml (EX-101.CAL) — 78KB
• iclr-20240930_def.xml (EX-101.DEF) — 281KB
• iclr-20240930_lab.xml (EX-101.LAB) — 554KB
• iclr-20240930_pre.xml (EX-101.PRE) — 453KB
• iclr-20240930_htm.xml (XML) — 1115KB

Business

Business ICON is a contract research organization ("CRO"), providing outsourced services on a global basis to pharmaceutical, biotechnology, medical device and government and public health organizations. We specialize in the strategic development, management and analysis of programs that support all stages of the clinical development process - from compound selection to Phase I-IV clinical studies. Our vision is to be the healthcare intelligence partner of choice by delivering industry leading solutions and best in class performance in clinical development. We believe that we are one of a select group of CROs with the expertise and capability to conduct clinical trials in the major therapeutic areas on a global basis and have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated "full service" solution. At September 30, 2024 we had approximately 42,250 employees in 106 locations in 55 countries. During the nine months ended September 30, 2024 we derived 37.8%, 50.7% and 11.5% of our revenue in the United States, Europe and Rest of World respectively (during the nine months ended September 30, 2023: 41.7%, 47.5% and 10.8% respectively). We began operations in 1990 and have expanded our business through organic growth, together with a number of strategic acquisitions to enhance our capabilities and expertise in certain areas of the clinical development process. We are incorporated in Ireland and our principal executive office is located at: South County Business Park, Leopardstown, Dublin 18, D18 X5R3, Republic of Ireland. The contact telephone number of this office is +353-1-291-2000. Recent developments Changes in Board of Directors composition On July 23, 2024, Ms. Joan Garahy retired from the Board of Directors and Ms. Anne Whitaker was appointed to the Board of Directors. Executive Leadership transition On April 3, 2024, the Company announced that Chief Financial Officer ("CFO"), Mr. Brendan

View Full Filing

View this 6-K filing on SEC EDGAR